v3.26.1
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating expenses:            
Research and development $ 1,486,825   $ 2,700,939   $ 3,671,143 $ 4,923,565
Selling, general and administrative 3,928,150   1,949,035   9,667,054 3,432,444
Operating loss (5,414,975)   (4,649,974)   (13,338,197) (8,356,009)
Change in fair value of derivative (314,013)   (194,526)   (1,166,043) (244,513)
Interest and other income (expense), net (141,276)   (138,761)   (678,113) (235,417)
Loss before income taxes (5,870,264)   (4,983,261)   (15,182,353) (8,835,939)
Income tax benefit (expense)    
Net loss and comprehensive loss $ (5,870,264) $ (9,312,089) $ (4,983,261) $ (3,852,678) $ (15,182,353) $ (8,835,939)
Net loss per share of common stock, basic $ (0.45)   $ (1.14)   $ (1.32) $ (2.20)
Net loss per share of common stock, diluted $ (0.45)   $ (1.14)   $ (1.32) $ (2.20)
Weighted average number of shares used in computing net loss per share of common stock, basic 13,186,057   4,389,465   11,477,983 4,020,231
Weighted average number of shares used in computing net loss per share of common stock, diluted 13,186,057   4,389,465   11,477,983 4,020,231